MA46023A - Vaccin contre le virus de la grippe à large spectre - Google Patents

Vaccin contre le virus de la grippe à large spectre

Info

Publication number
MA46023A
MA46023A MA046023A MA46023A MA46023A MA 46023 A MA46023 A MA 46023A MA 046023 A MA046023 A MA 046023A MA 46023 A MA46023 A MA 46023A MA 46023 A MA46023 A MA 46023A
Authority
MA
Morocco
Prior art keywords
broad spectrum
influenza vaccine
spectrum influenza
vaccine
broad
Prior art date
Application number
MA046023A
Other languages
English (en)
French (fr)
Inventor
Kerim Babaoglu
Giuseppe Ciaramella
Jessica Anne Flynn
Eric Yi-Chun Huang
Lan Zhang
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA46023A publication Critical patent/MA46023A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA046023A 2015-10-22 2016-10-21 Vaccin contre le virus de la grippe à large spectre MA46023A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245031P 2015-10-22 2015-10-22
US201562245225P 2015-10-22 2015-10-22
US201562247501P 2015-10-28 2015-10-28
US201562248248P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
MA46023A true MA46023A (fr) 2019-07-03

Family

ID=58558155

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046023A MA46023A (fr) 2015-10-22 2016-10-21 Vaccin contre le virus de la grippe à large spectre

Country Status (12)

Country Link
US (1) US20180311336A1 (cg-RX-API-DMAC7.html)
EP (1) EP3365007A4 (cg-RX-API-DMAC7.html)
JP (3) JP7384512B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180096591A (cg-RX-API-DMAC7.html)
CN (2) CN118846026A (cg-RX-API-DMAC7.html)
AU (2) AU2016342048B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008078A2 (cg-RX-API-DMAC7.html)
CA (1) CA3003103A1 (cg-RX-API-DMAC7.html)
MA (1) MA46023A (cg-RX-API-DMAC7.html)
MX (2) MX2018004916A (cg-RX-API-DMAC7.html)
RU (1) RU2018118337A (cg-RX-API-DMAC7.html)
WO (1) WO2017070620A2 (cg-RX-API-DMAC7.html)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364982A4 (en) 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
TN2018000152A1 (en) 2015-10-22 2019-10-04 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
AU2017268394A1 (en) 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
WO2018075592A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
EP3538146A4 (en) * 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
LT3571224T (lt) 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
JP7651261B2 (ja) 2017-03-24 2025-03-26 バイオエヌテック エスエー 免疫応答を刺激するための方法及び組成物
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3673069A1 (en) 2017-08-22 2020-07-01 CureVac AG Bunyavirales vaccine
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
KR102809623B1 (ko) 2018-01-29 2025-05-16 머크 샤프 앤드 돔 엘엘씨 안정화된 rsv f 단백질 및 그의 용도
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
DE202019006108U1 (de) 2018-04-17 2024-12-16 CureVac SE Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
JP7425066B2 (ja) * 2018-09-04 2024-01-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
MX2021005257A (es) 2018-11-06 2021-06-18 Boehringer Ingelheim Vetmedica Gmbh Composicion inmunogenica contra el subtipo h5 del virus de la influenza aviar.
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
WO2020161342A1 (en) 2019-02-08 2020-08-13 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
US12496336B2 (en) * 2019-05-16 2025-12-16 Vanderbilt University Peptide vaccine based on a new universal influenza a hemagglutinin head domain epitope and human monoclonal antibodies binding thereto
WO2020254535A1 (en) 2019-06-18 2020-12-24 Curevac Ag Rotavirus mrna vaccine
WO2021028439A1 (en) 2019-08-14 2021-02-18 Curevac Ag Rna combinations and compositions with decreased immunostimulatory properties
WO2021076805A1 (en) * 2019-10-15 2021-04-22 Moderna TX, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
JP2023507465A (ja) 2019-12-20 2023-02-22 キュアバック エスイー 核酸を送達するための脂質ナノ粒子
EP3886897A1 (en) 2020-02-04 2021-10-06 CureVac AG Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
GB2605312B (en) 2020-03-23 2024-06-26 Hdt Bio Corp Compositions and methods for delivery of RNA
CN116583296A (zh) * 2020-03-31 2023-08-11 宾夕法尼亚大学理事会 使用核苷修饰mrna的通用流感疫苗
RU2742336C1 (ru) * 2020-04-06 2021-02-04 Общество с ограниченной ответственностью "ВиЭй Фарма" Кросс-реактивная рекомбинантная вакцина против вируса гриппа а человека
KR102813425B1 (ko) 2020-04-22 2025-05-28 바이오엔테크 에스이 코로나바이러스 백신
WO2021222832A1 (en) * 2020-05-01 2021-11-04 Meso Scale Technologies, Llc. Viral serology ace2 competition assays
CN116322758A (zh) * 2020-05-29 2023-06-23 库尔维科欧洲股份公司 基于核酸的组合疫苗
US20230256090A1 (en) 2020-06-29 2023-08-17 Glaxosmithkline Biologicals Sa Adjuvants
EP4175967A2 (en) 2020-07-02 2023-05-10 Life Technologies Corporation Trinucleotide cap analogs, preparation and uses thereof
GB202011367D0 (en) * 2020-07-22 2020-09-02 Micropore Tech Limited Method of preparing liposomes
WO2022023559A1 (en) 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20230277457A1 (en) * 2020-08-06 2023-09-07 Modernatx, Inc. Methods of preparing lipid nanoparticles
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022043551A2 (en) 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
KR20230065321A (ko) * 2020-09-07 2023-05-11 인터벳 인터내셔널 비.브이. Ha 항체-양성 표적을 위한 ha 스템 백신
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
IL302482A (en) 2020-11-05 2023-06-01 Neoimmunetech Inc Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
US20240299309A1 (en) 2020-12-22 2024-09-12 CureVac SE Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
AU2022208057A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
EP4087938A2 (en) 2021-01-27 2022-11-16 CureVac AG Method of reducing the immunostimulatory properties of in vitro transcribed rna
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
US20240100145A1 (en) * 2021-03-05 2024-03-28 Moderna TX, Inc. Vlp enteroviral vaccines
WO2022200582A1 (en) * 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
CA3171429A1 (en) 2021-03-31 2022-09-30 Alexander SCHWENGER Syringes containing pharmaceutical compositions comprising rna
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN117642179A (zh) * 2021-05-19 2024-03-01 第一三共株式会社 流感病毒核酸脂质颗粒疫苗
WO2022248353A1 (en) 2021-05-24 2022-12-01 Glaxosmithkline Biologicals Sa Adjuvants
CA3224175A1 (en) * 2021-06-18 2022-12-22 Sanofi Multivalent influenza vaccines
EP4366768A4 (en) * 2021-07-09 2025-05-21 ModernaTX, Inc. Pan-human coronavirus vaccines
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
CN117940158A (zh) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
AU2022351009A1 (en) 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
JP2024535354A (ja) * 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
CN118510549A (zh) * 2021-09-22 2024-08-16 圣诺制药公司 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物
CN113827714B (zh) * 2021-09-26 2023-07-14 华南农业大学 一种h7n9亚型禽流感病毒样颗粒疫苗制剂及制备和应用
CA3237658A1 (en) * 2021-10-08 2023-04-13 Pfizer Inc. Immunogenic lnp compositions and methods thereof
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
IL312502A (en) * 2021-11-05 2024-07-01 Sanofi Sa Hybrid multivalent influenza vaccines containing hemagglutinin and neuraminidase and methods of using them
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2023125889A1 (en) * 2021-12-31 2023-07-06 Suzhou Abogen Biosciences Co., Ltd. Quadrivalent mrna vaccines for influenza viruses
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
KR20250075664A (ko) 2022-09-26 2025-05-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 바이러스 백신
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
TW202440929A (zh) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 用於感染性疾病的組合物和方法
AU2023394992A1 (en) * 2022-12-15 2025-07-31 Sanofi Pasteur Inc. Mrna encoding influenza virus-like particle
CN118256522A (zh) * 2022-12-19 2024-06-28 斯微(上海)生物科技股份有限公司 一种广谱流感mRNA疫苗
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions
EP4658239A1 (en) 2023-02-03 2025-12-10 GlaxoSmithKline Biologicals S.A. Rna formulation
GB202302092D0 (en) 2023-02-14 2023-03-29 Glaxosmithkline Biologicals Sa Analytical method
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN121001738A (zh) * 2023-04-27 2025-11-21 葛兰素史克生物有限公司 流感病毒疫苗
WO2024223724A1 (en) 2023-04-27 2024-10-31 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2025011529A2 (en) 2023-07-07 2025-01-16 Shanghai Circode Biomed Co., Ltd. Circular rna vaccines for seasonal flu and methods of uses
WO2025012461A1 (en) 2023-07-13 2025-01-16 Sanofi Methods and compositions for analyzing messenger rna
WO2025045142A1 (en) 2023-08-29 2025-03-06 Shanghai Circode Biomed Co., Ltd. Circular rna encoding vegf polypeptides, formulations, and methods of uses
WO2025092866A1 (zh) * 2023-10-31 2025-05-08 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
WO2025102071A1 (en) * 2023-11-09 2025-05-15 The General Hospital Corporation Hemagglutinin polypeptides and uses thereof
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
GB202404607D0 (en) 2024-03-29 2024-05-15 Glaxosmithkline Biologicals Sa RNA formulation
WO2025259931A1 (en) 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2676072B1 (fr) * 1991-05-03 1994-11-18 Transgene Sa Vecteur de delivrance d'arn.
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP3051957B2 (ja) 1997-08-28 2000-06-12 榮太郎 清水 融雪機
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
AU2002319668A1 (en) 2001-07-27 2003-02-17 President And Fellows Of Harvard College Laminar mixing apparatus and methods
US20060051424A1 (en) 2001-10-03 2006-03-09 Johns Hopkins University Compositions of oral gene therapy and methods of using same
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
JP2007532629A (ja) 2004-04-15 2007-11-15 キアスマ， インコーポレイテッド 生物学的障壁を横切る透過を促進し得る組成物
ES2407979T3 (es) 2004-12-10 2013-06-17 Kala Pharmaceuticals, Inc. Copolímeros de bloques de poli(éter-anhídrido) funcionalizados
NZ562064A (en) 2005-04-01 2011-03-31 Intezyne Technologies Inc Polymeric micelles for drug delivery
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
CN101242858B (zh) 2005-06-16 2012-12-19 尼克塔治疗公司 具有可降解键的轭合物以及用于制备这种轭合物的聚合物试剂
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US20100215580A1 (en) 2006-09-08 2010-08-26 The Johns Hopkins University Compositions and methods for enhancing transport through mucus
EP2120859B1 (en) 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
EA023175B1 (ru) 2007-09-28 2016-05-31 Бинд Терапьютикс, Инк. Таргетирование раковых клеток с использованием наночастиц
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
PT2285350T (pt) 2008-06-16 2018-01-04 Pfizer Métodos para a preparação de copolímeros em dibloco funcionalizados com agente de direcionamento para utilização no fabrico de nanopartículas terapêuticas
HUE047004T2 (hu) 2008-06-16 2020-04-28 Pfizer Hatóanyaggal töltött polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
WO2010060430A2 (en) * 2008-11-28 2010-06-03 Statens Serum Institut Optimized influenza vaccines
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
JP5622254B2 (ja) 2009-03-31 2014-11-12 国立大学法人東京大学 二本鎖リボ核酸ポリイオンコンプレックス
US8287910B2 (en) 2009-04-30 2012-10-16 Intezyne Technologies, Inc. Polymeric micelles for polynucleotide encapsulation
CA2816925C (en) * 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
PT2525815E (pt) 2010-01-24 2015-03-05 Novartis Ag Micropartículas de polímero biodegradável irradiadas
US20110262491A1 (en) 2010-04-12 2011-10-27 Selecta Biosciences, Inc. Emulsions and methods of making nanocarriers
JP2013531634A (ja) 2010-05-24 2013-08-08 メルク・シャープ・エンド・ドーム・コーポレイション オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
US20130196948A1 (en) 2010-06-25 2013-08-01 Massachusetts Insitute Of Technology Polymers for biomaterials and therapeutics
SI2590676T1 (sl) * 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
ES2586580T3 (es) * 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
AU2011291522A1 (en) * 2010-08-20 2013-01-24 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza A virus M2E
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US20150056300A1 (en) 2010-10-22 2015-02-26 Bind Therapeutics, Inc. Therapeutic nanoparticles with high molecular weight copolymers
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
US20120189700A1 (en) 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
AU2012212463B2 (en) * 2011-01-31 2016-07-07 Nanotherapeutics, Inc. Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
WO2012109121A1 (en) 2011-02-07 2012-08-16 Purdue Research Foundation Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
EP2691078A1 (en) 2011-03-31 2014-02-05 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
WO2012135805A2 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
WO2012131104A2 (en) 2011-03-31 2012-10-04 Ingell Technologies Holding B.V. Biodegradable compositions suitable for controlled release
US8691750B2 (en) * 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
LT2717893T (lt) * 2011-06-08 2019-08-12 Translate Bio, Inc. Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
CN106995488A (zh) * 2011-06-20 2017-08-01 高等教育联邦系统-匹兹堡大学 计算优化的宽反应性的h1n1流感抗原
SG10201605537XA (en) * 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
EP2734184B1 (en) 2011-07-21 2018-03-28 Croda International Plc Branched polyether-polyamide block copolymers and methods of making and using the same
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CN103930135A (zh) 2011-08-31 2014-07-16 马林克罗特有限公司 使用h-膦酸酯的纳米颗粒peg修饰
US20150017245A1 (en) 2011-09-22 2015-01-15 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
CA2849822C (en) * 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
EP4074694A1 (en) 2011-10-27 2022-10-19 Massachusetts Institute Of Technology Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
SMT202200355T1 (it) * 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
CA2863632C (en) 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
JP6182159B2 (ja) 2012-02-03 2017-08-16 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー フェノール性単量体から誘導された高分子生体材料およびその医療用途
WO2013120052A1 (en) 2012-02-10 2013-08-15 E. I. Du Pont De Nemours And Company Preparation, purification and use of high-x diblock copolymers
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
WO2014089486A1 (en) * 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
CN104902925A (zh) * 2013-01-10 2015-09-09 诺华股份有限公司 流感病毒免疫原性组合物及其应用
PL2970456T3 (pl) * 2013-03-14 2022-01-31 Translate Bio, Inc. Sposoby i kompozycje do dostarczania przeciwciał kodowanych mrna
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
PL4332576T3 (pl) * 2013-03-15 2025-09-08 Translate Bio, Inc. Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
WO2015024669A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
WO2015149944A2 (en) * 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
RS66380B1 (sr) * 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
CN107427571A (zh) * 2014-12-31 2017-12-01 美利坚合众国,由健康及人类服务部部长代表 基于纳米颗粒的新型多价疫苗
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions

Also Published As

Publication number Publication date
EP3365007A2 (en) 2018-08-29
AU2016342048A1 (en) 2018-06-07
AU2016342048B2 (en) 2022-09-08
WO2017070620A2 (en) 2017-04-27
MX2022006603A (es) 2022-07-11
JP7491639B2 (ja) 2024-05-28
RU2018118337A (ru) 2019-11-25
JP2024105503A (ja) 2024-08-06
US20180311336A1 (en) 2018-11-01
CA3003103A1 (en) 2017-04-27
JP2018537521A (ja) 2018-12-20
KR20180096591A (ko) 2018-08-29
WO2017070620A3 (en) 2017-07-13
BR112018008078A2 (pt) 2018-11-13
CN118846026A (zh) 2024-10-29
MX2018004916A (es) 2019-07-04
AU2022218595A1 (en) 2022-09-29
CN109310751A (zh) 2019-02-05
EP3365007A4 (en) 2019-07-03
JP7384512B2 (ja) 2023-11-21
JP2022031942A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
MA46023A (fr) Vaccin contre le virus de la grippe à large spectre
MA52262A (fr) Vaccin à large spectre contre le virus de la grippe
EP3463447A4 (en) INFLUENZA VIRUS PROTECTION Vaccines
MA46766A (fr) Vaccin antigrippal
EP3247389A4 (en) INFLUENZAVIRUSSCHUTZIMPFPLÄNE
MA43762A (fr) Vaccin contre le rsv
MA46317A (fr) Vaccin contre le virus respiratoire syncytial
IL259077A (en) Vaccines against hepatitis b virus
EP3480307A4 (en) NEW GENETICALLY MODIFIED VACCINIA VIRUS
MA47787A (fr) Vaccin contre le virus respiratoire syncytial
LT3393510T (lt) Zikos viruso vakcina
MA46584A (fr) Vaccin contre le cytomégalovirus humain
MA46316A (fr) Vaccin contre le cytomégalovirus humain
LT3718565T (lt) Kvėpavimo takų virusų vakcinos
DK3805376T3 (da) Modificeret virus
MA46024A (fr) Vaccin contre le virus de l'herpès simplex
EP3659614C0 (en) ONCOLYTIC VACCINIA VIRUS
BR112017028011A2 (pt) vacinas de gripe correspondentes antigenicamente
EP4233846C0 (en) PHARMACEUTICAL FORMULATIONS
MA45381A (fr) Formulation de vaccin contre le vih
EP3369436A4 (en) PLASMA STERILIZATION DEVICE
EP3385286A4 (en) VACCINE FANTASY WITH INCREASED IMMUNOGENITY
MA40772A (fr) Variants du virus de la grippe a
FR24C1042I2 (fr) Vaccin à large spectre contre un réovirus aviaire
EP4122586C0 (en) PLASMA EXTRACTOR